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Abstract
Background: Nevirapine belongs to the group of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is
commonly administered in first-line treatment of HIV infection.
Objective: Systematic review and meta-analysis was undertaken to compare effectiveness of nevirapine-based
regimens with other antiretroviral schedules used as an initial treatment of HIV-infected antiretroviral-naive subjects.
Methods: Electronic databases (PubMed, EMBASE, the Cochrane Library, Trip Database) were searched up to 28
December 2012 for randomized controlled trials (RCTs) published as a full text and regarding nevirapine-based
regimens used as a initial treatment for HIV infection. Meta-analysis was performed with RevMan® V 5.2 software.
Results: Twelve RCTs were included in the systematic review and all of them were suitable for meta-analysis.
Results of the meta-analysis have shown that nevirapine, efavirenz, and ritonavir-boosted protease inhibitor, added
to the background regimens, were equally effective in terms of reaching undetectable plasma HIV RNA level as well
as risk of disease progression or death. Compared with ritonavir-boosted protease inhibitor-based regimens,
nevirapine-based regimens statistically significantly increased the risk of discontinuation of assigned treatment
(RR=3.10; 95% CI: 1.14-8.41; p<0.05).
Conclusions: Despite limited RCTs data available for particular comparisons, our results suggest that nevirapine-
based regimens may be considered for first-line treatment of HIV-infected adults, due to their comparable efficacy to
the other currently recommended initial antiretroviral therapies.
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Introduction
Although the efficacy of antiretroviral therapy in HIV-positive
patients is indisputable, the variability of antiretroviral regimens
used in clinical practice raises the question of the most
effective treatment schedules. A combination of three or more
drugs, known as highly active antiretroviral therapy (HAART), is
now typically used. HAART is effective at lowering viral load
and increasing CD4+ T cell levels [1]. According to the current
practice guidelines antiretroviral regimens based on the
combination of one non-nucleoside analogue reverse-
transcriptase inhibitor (NNRTI) (commonly efavirenz or
nevirapine) and two nucleoside analogue reverse transcriptase
inhibitors (NRTIs) are among the preferred combinations for
first-line antiretroviral therapy [2,3]. Such regimens have good
virological potency and require administration once or twice-
daily. Nevirapine, considered a “first-generation’’ NNRTI, has
proven long term-efficacy and generally good tolerability in
HIV-infected patients. Nevirapine is also used to prevent
vertical transmission of HIV [4]. The new extended release
formula of nevirapine facilitates therapy by reducing the
number of pills to one a day [5]. Nevirapine-based regimens
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are preferred in resource-limited settings because of the lower
cost in comparison with efavirenz, and the potential teratogenic
effects of efavirenz. This is important, especially in African
countries where the majority of antiretroviral treated adults are
women and pregnancy rates in this population are high [6,7]. In
light of numerous trials regarding the use of nevirapine in HIV-
infected patients we systematically reviewed and meta-
analyzed randomized controlled trial data in order to establish
the differences between nevirapine-based regimens and other
antiretroviral regimens used in HIV-infected patients not
previously treated with antiretroviral therapy.
Methods
This report was conducted according to the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) guidelines [8] and methods described in the
Cochrane Handbook [9]. A systematic search of electronic
databases and reference lists of all eligible studies published
up to December 2012 was conducted to identify all relevant
studies. The databases searched included Medline
via PubMed, EMBASE, the Cochrane Central Register of
Controlled Trials (CENTRAL), and the Trip Database. The
search strategy included MeSH and EMTREE terms, combined
with the Boolean logic operators AND and OR (Table 1). The
Cochrane Database of Systematic Reviews, PubMed and
EMBASE databases were also searched for review articles.
The search results were restricted to human studies, and
methodological filters were used for the selection of
randomized controlled trials (RCTs). Studies were considered
irrespective of language. We included all randomized controlled
trials published as a full text comparing nevirapine with any
other, commonly used treatment schedule in adult HIV-infected
patients without prior exposure to antiretroviral therapy (studies
assessing placebo as a comparator were excluded). Data
presented only at conference meetings in abstract form were
not included in the systematic review and meta-analysis, as the
reliability of such results is lower than published peer-reviewed
references. Studies including nevirapine administered to
patients in every treatment arm, or given to pregnant or
lactating women only for the prevention of mother-to-child
transmission, and studies conducted only on children and
infants were excluded. We also excluded studies conducted
exclusively in HIV-infected patients with other concurrent
infectious illnesses, such as hepatitis B, hepatitis C or
tuberculosis. We searched for outcome measures assessing
the clinical progression of disease or death, virological
response (defined as undetectable plasma HIV RNA), and the
safety profile (risk of adverse events and discontinuation of
study because of adverse events).
The search and selection of the trials were performed
independently by two reviewers (P.K., J.K.). All disagreements
were resolved by discussion with a third author (A.M.) to obtain
consensus. Full texts of articles were reviewed according to the
predefined inclusion or exclusion criteria. Data extracted by the
first reviewer (P.K.) were verified by the second reviewer (J.K.).
Extracted information included: study design, participant
characteristics, interventions, duration of treatment, and clinical
outcomes. To assess the methodological quality of included
trials, the Jadad scale was used [10] (Table 2). Reduction of
Risk Ratio (RR) was measured for data regarding the benefit of
treatment, while for negative endpoints the increase of RR was
assessed, all with 95% confidence intervals (CI). The results
obtained from separate trials were combined using appropriate
meta-analysis methods. An inverse variance and the Mantel-
Haenszel or DerSimonian-Laird methods were used according
to the data input and heterogeneity of test results. Clinical
heterogeneity was assessed by examining the characteristics
of the featured studies, whereas the statistical heterogeneity
was assessed using the chi-square test, with a significance
level of p<0.10. A fixed effects model was used when no
statistical heterogeneity was detected; otherwise the random
effects model was used. Meta-analysis was performed with
RevMan® V 5.2 software.
Table 1. MeSH subject headings and EMTREE keywords used in search strategy construction (last updated: 28.12.2012).
Keywords (combined with boolean logical operators: AND, OR)
Medical condition
(Viruses, Human Immunodeficiency) OR (AIDS Virus) OR (AIDS Viruses) OR (Virus, AIDS) OR (Viruses, AIDS) OR (HTLV-III) OR (Human
Immunodeficiency Virus) OR (Human Immunodeficiency Viruses) OR (Human T Cell Lymphotropic Virus Type III) OR (Human T Lymphotropic Virus
Type III) OR (Human T-Cell Leukemia Virus Type III) OR (Human T-Cell Leukemia Virus Type III) OR (Human T-Cell Lymphotropic Virus Type III) OR
(Human T-Cell Lymphotropic Virus Type III) OR (Immunodeficiency Virus, Human) OR (Immunodeficiency Viruses, Human) OR (LAV-HTLV-III) OR
(Lymphadenopathy-Associated Virus) OR (Lymphadenopathy-Associated Virus) OR (Lymphadenopathy-Associated Viruses) OR (Virus,
Lymphadenopathy-Associated) OR (Viruses, Lymphadenopathy-Associated) OR (Virus, Human Immunodeficiency) OR (Acquired Immune Deficiency
Syndrome Virus) OR (Acquired Immunodeficiency Syndrome Virus) OR (aids associated lentivirus) OR (aids associated retrovirus) OR (aids
associated virus) OR (aids related virus) OR HIV OR (immunodeficiency associated virus) OR (immunodeficiency viruses primate) OR lav OR (LAV
(AIDS)) OR (lentiviruses, primate) OR (lymphadenopathy associated retrovirus) OR (Lymphadenopathy associated virus) OR (virus,
lymphadenopathy associated)
Intervention
(Nevirapine OR NVP OR Viramune OR (Promeco Brand of Nevirapine) OR (Cahill May Roberts Brand of Nevirapine) OR (BI-RG-587) OR (BI RG
587) OR BIRG587 OR birg 587 OR ciplanevimune OR nevimune OR viramun OR (viramune xr))
Methodological limits
PubMed: Humans, Randomized Controlled Trial; EMBASE: Humans, Randomized Controlled Trial, Embase only; CENTRAL: No limits applied; word
variations have been searched
doi: 10.1371/journal.pone.0076587.t001
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Results
The electronic search yielded 783 items after duplicates
were removed. The selection of titles and abstracts resulted in
60 potentially relevant full-text articles, of which 49 references
were excluded due to the reasons presented in Figure 1.
Twelve studies met the predefined inclusion criteria for
systematic review and were suitable for quantitative synthesis
(meta-analysis). The flow of selection through the different
phases of the systematic review is shown in Figure 1.
Twelve randomized controlled trials published in English as
peer-reviewed articles were included. These included studies
were grouped in the following way. Firstly, background
regimen, common in compared groups, was identified. Active
drugs added to the common background regimen were
considered as comparators. Two different regimens adequate
for comparisons with nevirapine were identified: 1 NNRTI or
bPI (ritonavir-boosted protease inhibitor), all the above added
to specified background regimens. We did not take into
consideration regimens containing unboosted PI and triple
NRTIs regimens as they are no longer used in clinical practice.
A predefined inclusion criterion for studies was the absence
of any prior treatment with antiretroviral therapy. Finally, trials
recruiting patients with limited previous exposure to
antiretroviral therapy were included (Table 3). Data of clinical
relevant endpoints reflecting advances in the treatment of HIV
infection were extracted from the studies. Disease progression
was evaluated according to the Centers for Disease Control
(CDC) classification [11] or WHO guidelines, although
definitions of this endpoint were not consistent across the
included studies. Disease progression was determined by the
occurrence of clinical features indicating a higher CDC/WHO
stage (most often: new C or B/C events or new 3/4 AIDS-
defining events) and predominately, but not always, the
occurrence of death.
Plasma viral load (pVL) is a globally accepted endpoint used
to measure the efficacy of antiretroviral drugs [12]. Available
data of virological responses in the included studies were
reported as plasma HIV RNA level below: 50 and 400
copies/ml. It should be noted that the suppression of pVL to 50
copies/ml is a better predictor for durable virological success
than a suppression to <400-500 copies/ml [13,14]. Data for
nevirapine administered in different doses in one study were
aggregated. For safety analysis an overall risk of grade 3/4
adverse events was assessed when it was possible; otherwise
clinical adverse events data were included.
The characteristics of studies included in this report are
presented in Table 3. All of studies included in the systematic
review were open-label. Three of the included trials provided
information about allocation concealment. Most of the trials
included data about patient withdrawal and drop-out from the
study. Jadad scores ranged from 1 to 3, mostly due to a lack of
blinding and insufficient details about randomization methods
used (Table 2).
Effectiveness of adding nevirapine vs one non-
nucleoside reverse transcriptase inhibitor (NNRTI) to
the background regimen
All studies [15,16,17,18,19,20] suitable for inclusion for the
comparison of nevirapine vs one NNRTI evaluated efavirenz as
NNRTI. This means that all comparisons were performed
between nevirapine and efavirenz. The FIRST substudy [17]
included patients with previous limited exposure to antiretroviral
therapy. Three studies evaluated patients during the course of
48 weeks, and in the other two trials the follow-up period lasted
3 to 5 years (median). Studies were heterogeneous regarding
baseline plasma HIV RNA level (>500 to >55 000 copies/ml).
Data for nevirapine in different doses in two arms in the 2NN
[19] study were aggregated. The differences between
nevirapine and efavirenz were not statistically significant for the
proportion of patients with disease progression or death
(RR=0.78; 95% CI: 0.53-1.16; p>0.05), nor for the proportion of
patients with virological response (plasma viral loads below
Table 2. Methodological quality of included RCTs.
Study (acronym if stated) Jadad score Allocation concealment
 1 2 3 4 5 Total  
Gaytán 2004 [15] 1 0 0 0 0 1 Not reported
Núñez 2002, SENC [16] 1 0 0 0 1 2 Not reported
van den Berg-Wolf 2008 [17], substudy of FIRST [18] 1 0 0 0 0 1 Not reported
van Leth 2004, 2NN [19] 1 0 0 0 1 2 Described
Wester 2010, TSHEPO [20] 1 0 0 0 1 2 Not reported
Dejesus 2011, NEWART [21] 1 1 0 0 1 3 Described
Harris 2009 [22] 1 0 0 0 0 1 Not reported
Lapadula 2008 [23] 1 0 0 0 1 2 Not reported
Lockman 2010, OCTANE [24] 1 0 0 0 1 2 Not reported
Lockman 2012, OCTANE [25] 1 0 0 0 1 2 Described
Lowe 2005, ARES [26] 1 0 0 0 1 2 Not reported
Soriano 2011, ARTEN [27] 1 0 0 0 1 2 Not reported
1 - Was the study described as randomized?; 2 - Was the method of randomization described and appropriate?; 3 - Was the study described as double blind?; 4 - Was the
method of blinding described and appropriate?; 5 - Were withdrawals and dropouts described?
doi: 10.1371/journal.pone.0076587.t002
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400 copies/ml: RR=1.00; 95% CI: 0.95-1.05; p>0.05 and below
50 copies/ml: RR=1.03; 95% CI: 0.95-1.11; p>0.05) in weeks
48-52. The results of meta-analysis showed that the risk of
assigned treatment discontinuation due to intolerance was
comparable in both arms (RR=1.25; 95% CI: 0.99-1.60;
p>0.05); Figure 2.
Effectiveness of adding nevirapine vs ritonavir-boosted
protease inhibitor (bPI) to the background regimen
Of seven studies ( [21,22,23,24,25,26,27]) comparing
nevirapine vs ritonavir-boosted protease inhibitor (bPI) only
three trials included truly antiretroviral naive patients; four other
studies recruited patients with limited prior antiretroviral
exposure. All patients in the OCTANE 2010 [24] trial had
received a single-dose of nevirapine six or more months before
enrollment, for the prevention of mother-to-child HIV
transmission. In most studies results for a 48-week follow-up
period were reported. Additionally, one study [23] lasting only
12 weeks was prematurely discontinued due to virological
failure, and as such its efficacy results seemed to be unsuitable
for the meta-analysis. In the ARES [26] trial, data presented for
disease progression were defined as the occurrence of new
CDC events only (B/C events), and there was no information
about deaths in the whole article (of note: in the OCTANE
study disease progression was defined as the occurrence of a
new CDC event or death). No statistically significant
Figure 1.  PRISMA flow diagram for selection of studies identified in the systematic review.  
doi: 10.1371/journal.pone.0076587.g001
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Table 3. Characteristics of the randomized controlled trials for nevirapine compared to different regimens used to treat
antiretroviral–naive HIV-infected adult patients.
Study author, year of
publication, study type, sites Population
Study
duration Interventions& Study outcomes#
background regimen (2 NRTIs/2NRTIs+1PI) + nevirapine vs background regimen + 1NNRTI
Gaytán 2004 [15], RCT, open-
label, 1 center in Mexico
ART-naive, age ≥18 years, pVL
>55 000 copies/ml, N=58
48 weeks
A: AZT + 3TC + NVP, N=28 B: AZT + 3TC
+ EFV, N=30
• disease progression or death,
• percentage of patients with pVL <400
copies/ml (week 48),
• discontinuation of therapy due to
adverse events
Núñez 2002, SENC [16],
RCT, open-label, 1 center in
Spain
ART-naive, age > 18 years, pVL:
500-100 000 copies/ml, N=67
48 weeks
A: ddI + d4T + NVP, N=36B: ddI + d4T +
EFV, N=31
• percentage of patients with pVL <50
copies/ml (week 48),
• discontinuation of therapy due to
adverse events
van den Berg-Wolf 2008,
NNRTI [17] substudy of
FIRST trial [18], RCT, open-
label, 17 clinical trials units at
80 sites in the United States
ART-naive (less than 4 weeks of
prior NRTI use or 1 week of 3TC
use was allowed), age ≥13
years, N=228
median -5
years
patients randomized to NNRTI+NRTIs
strategy (N=110) or PI+NNRTI+NRTIs
strategy (118) and then randomized to: A:
EFV, N=111; B: NVP, N=117 (NRTIs
included: ABC + 3TC or ddI + d4T or AZT
+ 3TC or d4T + 3TC; PI included: NFV,
INV, /r
• disease progression or death,
• percentage of patients with pVL <50
copies/ml (week 52),
• discontinuation of therapy due to
adverse events
van Leth 2004, 2NN [19],
RCT, open-label, centers in
North and South America,
Australia, Europe, South
Africa and Thailand
ART-naive, age ≥16 years, pVL
>5 000 copies/ml, N=1216
48 weeks
A: d4T + 3TC + NVP (400 mg once daily),
N=220; B: d4T + 3TC + NVP (200 mg
twice daily), N=387; C: d4T+ 3TC+ EFV
(600 mg once daily), N=400
• disease progression or death,
• percentage of patients with pVL <50
copies/ml (week 48),
• discontinuation of therapy due to
adverse events
Wester 2010, TSHEPO [20],
RCT, open-label, one center
in Botswana
ART-naive, age ≥ 18 years, pVL
>55 000 copies/ml, N=650
3 years
A: 2NRTI + NVP, N=325; B: 2NRTI + EFV,
N=325 (2 NRTI consisted: AZT + 3TC or
AZT + ddI or d4T + 3TC)
• percentage of patients with pVL <400
copies/ml (week 52),
• in safety analysis treatment-modifying
toxicities were evaluated (not suitable for
meta-analysis)
background regimen (2 NRTIs) + nevirapine vs background regimen + bPI
Dejesus 2011, NEWART [21],
RCT, open-label, 18 study
sites in United States
ART-naive (up to 10 days of
prior NRTIs or NNRTIs, all other
classes of antiretroviral agents
was allowed up to 2 weeks),
CD4 <400 cells mm3 (men),
<250 cells mm3 (women),
N=154
48 weeks
A: TDF + FTC + NVP, N=76; B: TDF +
FTC + ATV/r, N=78 (2 patients were
excluded from the analyses due to
methodological error)
• proportion of patients with pVL <50
copies/ml (week 48),
• discontinuation of therapy due to
adverse events
Harris 2009 [22], RCT, open-
label, centers in Canada,
France, Spain, Argentina
ART-naive, age ≥ 18 years, pVL
>5 000 copies/ml, N=77
96 weeks
A: AZT + 3TC + NVP, N=26; B: AZT + 3TC
+ LPV/r, N=25
• percentage of patients with pVL<50 ml
(week 48 and 96),
• discontinuation of therapy due to
adverse events
Lapadula 2008 [23] RCT,
open-label, 1 center in Italy@
ART-naive, age >18 years, CD4
cell count <400 cells/mm3
(men), <250 cells/mm3 (women),
N=14
12 weeks
A: TDF + FTC + NVP, N=7; B: TDF + FTC
+ ATV/r, N=7
• efficacy data reported in study were not
suitable for meta-analysis,
• discontinuation of therapy due to
adverse events
Lockman 2010, OCTANE [24],
RCT, open label, centers in
Botswana, Kenya, Malawi,
South Africa, Uganda,
Zambia, and Zimbabwe
ART-naive (all participants had
received single-dose of NVP≥6
months before enrollment, up to
10 weeks of prior AZT was
allowed), CD4 <200 cells/mm3,
N=243
≥48 weeks
A: TDF + FTC + NVP, N=123; B: TDF +
FTC + LPV/r, N=120 (2 women did not
received study medication and were
excluded from the analyses)
• disease progression or death,
• in the efficacy outcomes virological
failure was defined as a composite
endpoint (not suitable for meta-analysis),
• risk of grade 3 or higher adverse
events,
• discontinuation of therapy due to
adverse events
Nevirapine in HIV-Infected ART-Naive Patients
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differences between groups were observed in regards to the
risk of disease progression or death (RR=1.01; 95% CI:
0.65-1.58; p>0.05), or proportions of patients with plasma viral
loads <50 copies/ml at week 48 (RR=0.90; 95% CI: 0.77-1.06;
p>0.05). While there were no statistically significant differences
between analyzed regimens with respect to incidences of
adverse events of grade 3/4 (RR=1.34; 95% CI: 0.68-2.66;
p>0.05), risk of treatment discontinuation due to adverse
events was statistically significantly higher in the nevirapine
group compared to the 2 PI-based regimen (RR=3.10; 95% CI:
1.14-8.41); Figure 3.
Discussion
To our knowledge this is the first broad systematic review
containing meta-analysis that compares nevirapine-based
therapy with other antiretroviral regimens used to treat
antiretroviral-naive HIV-infected adult patients. The overall
results of the performed meta-analysis show that the efficacy of
nevirapine is comparable to efavirenz and ritonavir-boosted
protease inhibitors when added to the background regimen
(usually 2 NRTIs) in the target population of treatment-naive
adult HIV-infected patients. These results are supported by
clinical guidelines that recommend the above regimens as
initial therapeutic options for HIV infection. Our results are also
consistent with previous meta-analyses, showing that
nevirapine and efavirenz in combination with 2 NRTIs given to
antiretroviral-naive HIV-infected patients have similar efficacy
[28]. It should be noted that we confirm the efficacy results of
Mbuagbaw et al. [28] despite excluding patients with
concomitant tuberculosis and data from meeting abstracts. The
reasons for excluding patients with concurrent HIV infection
and tuberculosis are based on the WHO guidelines that
recommend treatment with efavirenz but not nevirapine in
individuals co-infected with tuberculosis and HIV who are
receiving rifampicin-based therapy [29]. The results obtained in
the presented meta-analysis also confirm previous findings
where combined data from two studies showed similar efficacy
of nevirapine versus efavirenz in combination with stavudine
and lamivudine (2 NRTIs) for first-line treatment of HIV
infection [30].
The main limitation of the conducted meta-analysis was the
number of trials available for particular comparisons and
heterogeneity of the included studies regarding background
regimens, baseline characteristics of randomized patients
(especially proportions of patients in various stages of
disease), lengths of follow-up periods, and differences in the
analyzed endpoint definitions. Some of the included studies
recruited patients with previous limited exposure to
antiretroviral therapy, for example single exposure to
nevirapine for the prevention of mother-to-child transmission of
HIV. Nevirapine, as well as other NNRTIs, has a low genetic
Table 3 (continued).
Study author, year of
publication, study type, sites Population
Study
duration Interventions& Study outcomes#
Lockman 2012, OCTANE [25],
RCT, open label, centers in
Botswana, Kenya, Malawi,
South Africa, Uganda,
Zambia, and Zimbabwe
ART-naive (up to 10 week of
prior AZT was allowed), women
only, CD4 <200 cells/mm3,
N=502
≥48 weeks
A: TDF + FTC + NVP, N=251; B: TDF +
FTC + LPV/r, N=251 (2 women did not
received study medication and were
excluded from the analyses)
• disease progression or death,
• virological failure was defined as a
composite endpoint (not suitable for meta-
analysis),
• risk of grade 3/4 adverse events,
• discontinuation of therapy due to
adverse events
Lowe 2005, ARES [26], RCT,
open-label, 7 centers in
Netherlands
ART-naive, age ≥18 years, pVL
≥5 000 copies/ml, N=71
48 weeks
B: ddI + 3TC + NVP, N=22; C: ddI + 3TC +
SQV/r, N=23
• disease progression or death,
• percentage of patients with pVL <50
copies/ml (week 48),
• risk of grade 3/4 adverse events,
• discontinuation of therapy due to
adverse events
Soriano 2011, ARTEN [27],
RCT, open-label, 68 centers
in Argentina, Germany, Italy,
Mexico, Poland, Romania,
Spain, Switzerland and the
UK
ART-naive (up to 7 days of prior
treatment was allowed), age ≥18
years, CD4 <400 cells/mm3
(men), <250 cells/mm3 (women),
N=576
48 weeks
A: TDF + FTC + NVP 200 mg twice daily,
N=192; B: TDF + FTC + NVP 400 mg once
daily, N=191; C: TDF + FTC + ATV/r,
N=193 (7 patients did not received study
medication and were excluded from the
analyses)
• percentage of patients with pVL <50
copies/ml (week 48),
• discontinuation of therapy due to
adverse events
3TC - lamivudine, ABC - abacavir, ART – antiretrovital therapy, ATV - atazanavir, AZT - zidovudine, d4T - stavudine, ddI - didanosine, EFV - efavirenz, FTC - emtricitabine,
NFV - nelfinavir, NNRTI - non-nucleoside reverse transcriptase inhibitor, NRTI - nucleoside reverse transcriptase inhibitor, NVP - nevirapine, PI - protease inhibitor, /r - low-
dose ritonavir, SQV - saquinavir, TDF - tenofovir, pVL - plasma HIV RNA.
#. study outcomes included in meta-analysis only.
& − interventions included in meta-analysis only.
@ prematurely stopped due to virological failure.
doi: 10.1371/journal.pone.0076587.t003
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barrier. The OCTANE study showed that resistance to
nevirapine occurred in 14% of women with previous exposure
to a single-dose of nevirapine, leading to decreased efficacy of
subsequent nevirapine-based treatments in comparison to
NNRTI-naive women [24,25]. However, excluding data from the
OCTANE 2010 [24] study did not changed the results of our
meta-analysis regarding efficacy (data not shown). The
heterogeneity of the included studies also regarded baseline
HIV RNA plasma levels, which was shown previously as a
predictive factor of reaching virological response to treatment
[25]. The results of meta-analysis performed by Raboud et al.
showed that patients with a baseline pVL <100 000 copies/ml
were more likely to achieve virological response (pVL <400
copies/ml and <20 copies/ml) than those with baseline plasma
Figure 2.  Forest plot of comparison: nevirapine vs 1 NNRTI (efavirenz) added to the background regimen.  
doi: 10.1371/journal.pone.0076587.g002
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HIV RNA level >100 000 copies/ml [31]. Guidelines for the
treatment of HIV-infected adults indicate low baseline viremia
as a predictor of virologic success during antiretroviral therapy
[3].
Moreover, in some studies the exact data on the particular,
clinically relevant outcomes were unavailable within the papers,
or they were not intended to be evaluated at all. Therefore, only
some of the identified studies could be included in a
Figure 3.  Forest plot of comparison: nevirapine vs bPI added to the background regimen.  
doi: 10.1371/journal.pone.0076587.g003
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quantitative analysis, and only some of the presented results
were suitable for meta-analysis, especially in the case of
efficacy evaluation (see Table 3).
Another limitation of the performed meta-analysis is the
absence of subgroup analysis according to background
regimens, due to the limited number of trials adequate for
inclusion in separate comparisons. Bartlett et al. [32] compared
different background regimens containing 2 NRTIs in efavirenz-
based therapy. Among the most effective NRTI regimens were
combinations of tenofovir and emtricitabine, while the less
effective regimens contain zidovudine and lamivudine (about
10% difference in the proportion of patients with the time to
loss of virologic response at week 48) [32]. The combination of
tenofovir plus emtricitabine is also among the most preferred
background regimens recommended in the current practice
guidelines [2,3]. However, in our meta-analysis the combination
of tenofovir and emtricitabine was only used as a background
regimen in trials comparing nevirapine and bPI-based therapy.
We did not perform subgroup analysis according to
nevirapine dosage. Most of the included studies analyzed
nevirapine given according to product characteristic -200 mg
twice a day. Three trials used nevirapine given as one daily
dose of 400 mg [19,20,24]. Nevertheless, results of the 2NN
study [19] showed similar rates of treatment failure when
nevirapine was given either once or twice daily.
It could be suggested that a network meta-analysis to
support the results obtained in direct analyses should be
performed. However, a mixed treatment comparison (MTC), a
special case of network meta-analysis combining direct
evidence and indirect evidence for particular pairwise
comparisons, has several limitations. First, the mixed treatment
approach is not a substitute for a large, well-designed
randomized controlled trial examining relative clinical efficacy
and safety. The validity of the adjusted indirect comparisons
(as with MTC) depends on the internal validity and
homogeneity of the included trials [33,34,35]. The mixed
treatment approach, while efficient in deriving treatment
estimates, is only as good as the data that are included. The
differences in study inclusion criteria meant disparity in the
patient populations between the trials. Unfortunately, relevant
clinical heterogeneity of the studies included in the performed
meta-analysis was found (as mentioned above, referring for
example to various agents from a particular class of
antiretroviral drugs used in a background therapy and different
stages of AIDS or baseline plasma HIV RNA levels in patients
participating in the included studies). In that situation the
strength of results from a mixed-treated comparison could be
limited. Moreover, Chou et al. provided evidence for a strong
discrepancy between direct and indirect comparisons in an
HIV-infected population. Crucially, while direct meta-analysis
showed that NNRTI-based regimens are better than PI-based
regimens (in terms of the virological response), an indirect
comparison revealed opposite results. Chou and colleagues
conclude that indirect comparisons within the mixed treatment
comparisons may not be reliable for such complex treatments
as HAART, especially in the case of paucity of data or
imbalance of available data concerning the evaluated drugs, or
significant heterogeneity among them [36].
According to the practice guidelines antiretroviral therapy in
HIV-infected patients should maximally and durably suppress
plasma HIV viral load and also reduce HIV-associated
morbidity and prolong the duration and quality of survival [3]. In
our meta-analysis the clinical endpoint, defined as disease
progression and/or death, showed no statistical difference
between nevirapine and efevirenz, nor between nevirapine and
ritonavir-boosted protease inhibitor (bPI) therapy. However, it
should be noted that not all of the included studies provided
data regarding the above endpoint (probably due to the short
follow-up time). What is more, the low rate of disease
progression or death reported in the included trials hampers
statistical analysis. However, results from long-term studies
assessing disease progression or death as a primary endpoint
could verify the results obtained in the performed meta-
analysis. The results obtained in a group of Senegalese
patients followed-up for a median of 48 months showed no
differences between nevirapine and efavirenz with respect to
the time to death or time to AIDS progression [37].
Results from other observational studies do not give a clear
answer on the issue of the higher efficacy of nevirapine or
efavirenz in the analyzed population. The above-mentioned
study conducted in Senegalese patients [37], as well as the
results of Patel et al. trial [38], showed comparable efficacy of
nevirapine and efavirenz in antiretroviral treatment-naive
patients. On the other hand, a prospective, observational trial
involving more than 20 000 patients showed a lower incidence
of death and AIDS-defining illness, as well as lower risk of
virologic failure at 12 months for efavirenz compared with
nevirapine [39]. Results obtained in routine clinical practice in
Europe also showed that patients starting efavirenz had a 48%
lower risk of discontinuation due to treatment failure compared
with the nevirapine group (however, in this trial about 60% of
patients were treatment-experienced) [40].
The overall toxicity profiles of nevirapine and other regimens
were comparable. However, a higher risk of treatment
discontinuation due to adverse events in comparison to
ritonavir-boosted protease inhibitor (bPI) was found. Due to
limited data it was also not possible to compare particular
adverse events between analyzed regimens. Regarding the
safety profile of nevirapine, hepatotoxicity and skin reactions,
especially rashes, are a special concern. In a large prospective
controlled trial that included nevirapine as a part of the
antiretroviral regimen, a high frequency of hepatotoxicity was
observed [41]. Data from the Asian observational database on
HIV treatment showed that the risk of discontinuation of
nevirapine therapy due to rashes and hepatotoxicity were 7%
and 2%, respectively [42]. Since the greatest risk of
hepatotoxicity and rashes occurs in the first 6 weeks of therapy
[43], patients should be closely monitored during the initiation
of nevirapine therapy. Among the specific factors, gender and
pretreatment CD4 count should be considered when
antiretroviral nevirapine-based therapy is initiated [3]. The
above factors are associated with the greater risk of hepatic
adverse events [43].
Results of previous meta-analyses comparing nevirapine and
efavirenz in combination with other antiretroviral agents
showed differences between both drugs in terms of toxicity
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[28,30]. Siegfried et al. [30] showed a higher frequency of
toxicity in participants receiving nevirapine compared to those
treated with efavirenz. However, the authors included only 2
trials where NNRTIs were given in combination with stavudine
and lamivudine [30]. Mbuagbaw et al. [28] performed a
comparison regarding particular adverse events reported in
nevirapine- and efavirenz-based regimens in antiretroviral-
naive HIV-infected patients. Efavirenz was connected with a
higher risk of central nervous system side-effects, while more
patients with raised transaminases and neutropenia were
reported in nevirapine arms [28]. In our meta-analysis
discontinuation of treatment due to adverse events showed a
tendency to favour efavirenz, although the observed effect was
not statistically significant. It should be noted that due to the
absence of central nervous system adverse events and limited
influence on lipid profiles, nevirapine is a safe therapeutic
option for patients at risk of depression or cardiovascular
disease [44].
In summary, our data demonstrate the comparable efficacy
of nevirapine-based therapy versus other regimens
recommended as initial therapy for HIV-infected patients (PI-
based and efavirenz-based treatments). Concerning safety,
special groups of patients can achieve significant clinical
benefits from nevirapine-based regimens. However, when
nevirapine treatment is initiated the risk of hepatotoxicity and
rashes should be taken into account. Despite the potential
limitations of the performed meta-analysis our results provide
important guidance for choosing first-line nevirapine-based
treatment for HIV-infected patients.
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